




Has the nomenclature NAFLD* been holding disease awareness back?

Calling it NAFLD overlooks the importance of metabolic dysfunction in the disease.¹



MAFLD† is more accurate nomenclature^{2,3}



Because diagnosis triggered by the presence of steatosis

⊕ ≥ 2 metabolic risk factors e.g. waist circumference, type 2 diabetes mellitus, hypertension etc.^{2,3}

MAFLD as a new nomenclature has been widely accepted^{2,4}

It is more meaningful and understandable for patients and healthcare providers.^{4,5}



Conclusions

- The name NAFLD may be a reason for the low recognition, poor public health response, funding and lack of drugs in the field.⁵
- Adopting the name MAFLD is already changing the approach to these patients, meaning that diagnosis and care is improving which will ultimately lead to better patient outcomes, as effective therapy should reduce steatosis and liver injury.^{2,3}

* NAFLD = Non-alcoholic fatty liver disease. † MAFLD = Metabolic-associated fatty liver disease.

References

1. Younossi Z, et al. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. 2. Shiha G, et al. Lancet Gastroenterol Hepatol. 2021;6:73–9. 3. Eslam M, et al. Hepatol Int. 2020;14:889–919. 4. Fouad Y, et al. J Hepatol. 2021;74:1254–1256. 5. Lazarus JV, et al. J Hepatol. 2020;72:14–24.



Flash for webinar